Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration

Date Published05/03/2023

Additional Reshoring Information:

Company/Division name Forge Biologics with Labcorp
Parent companyForge Biologics with Labcorp
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Reshoring
Year reshoring announced:2023
City reshored to:Columbus
State(s) reshored to:OH
If relevant, work nearshored to:-
Product(s) reshoredadeno-associated virus (AAV) mediated gene therapy
What domestic positive factors made reshoring more attractive?Better Control of Process/Delivery/Factory, Customization/Flexibility, Eco-system synergies, Higher productivity, Infrastructure, Lead time/Time to market, Lean/other business process improvement techniques, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market
Find Reshoring Articles